Hudson Bay Capital Management LP Bristol Myers Squibb CO Transaction History

Hudson Bay Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $2.77 Million - $3.32 Million	-45,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $1.07 Million - $1.25 Million	-20,000 Reduced 30.77%	45,000 $2.81 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $3.85 Million - $4.51 Million	65,000 New	65,000 $3.85 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $2.7 Million - $2.99 Million	-60,500 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $591,072 - $704,780	13,100 Added 27.64%	60,500 $2.89 Million
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $2.31 Million - $3 Million	47,400 New	47,400 $2.46 Million
Q2 2018 Aug 13, 2018	SELL	$50.53 - $62.98 $808,480 - $1.01 Million	-16,000 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$59.92 - $68.98 $2.04 Million - $2.35 Million	-34,000 Reduced 68.0%	16,000 $1.01 Million
Q4 2017 Feb 12, 2018	BUY	$59.94 - $65.35 $90,149 - $98,286	1,504 Added 3.1%	50,000 $3.06 Million
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $2.68 Million - $3.09 Million	48,496	48,496 $3.09 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.